Initial appetite suppression often occurs before significant weight loss becomes visible on the scale
Zhong, L
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
However, the timeline varies from one individual to another
In some cases, your healthcare provider might recommend blood tests to check your electrolyte levels or suggest making changes to your diet or exercise routine
This suit is without merit, and well defend ourselves vigorously against these claims, a CVS Health spokesperson said in an emailed statement